KURANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kura Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$9.36+0.28 (+3.08%)
Close on Oct 19, 2026
- Market cap
- $831.68M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.48 (−4.88%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Kura Oncology, Inc. reported revenue of $77.23M for the twelve months to Jun 30, 2026. Free cash flow was -$117.43M, down 195.6% from a year earlier.
Revenue
$77.23M
TTM Q2 2026
Operating income
-$318.09M
TTM Q2 2026
Free cash flow
-$117.43M
-195.6% vs. a year earlier
EPS, diluted
-$3.37
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $831.68M
- P/E ratio
- –
- Price to sales
- 10.77
- Price to book
- 17.17
- Dividend yield
- –
- Free cash flow yield
- -14.12%
Fundamentals
- Revenue
- $77.23M
- Net income
- -$296.78M
- EPS, diluted
- -$3.37
- Free cash flow
- -$117.43M
- Book value per share
- $0.55
- Diluted shares
- 89M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$77.23M
Operating income
-$318.09M
Net income
-$296.78M
EPS, diluted
-$3.37
Free cash flow
-$117.43M-195.6% YoY
Reported periodTrailing twelve months